A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS)

05/05/2020
14/03/2024
EU PAS number:
EUPAS30818
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

denovo-daa-pass-protocol_v3_abstract_01Aug2019

English (158.39 KB - PDF) View document
Updated protocol

denovo-daa-pass-protocol_v3_redacted

First published: 22/02/2024
English (328.84 KB - PDF) View document
Study results
Study results

b20146-abstract

English (185.62 KB - PDF) View document
Study report
Other information